CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that CAT-2054, the Company’s product candidate targeting the Sterol Regulatory Element-Binding Protein, or SREBP, pathway for the potential treatment of hypercholesterolemia, will be featured in a poster presentation at the upcoming National Lipid Association Scientific Sessions. The presentation will include data from the single ascending dose portion of the Phase 1 study of CAT-2054 in healthy volunteers. The National Lipid Association Scientific Sessions will be held June 11 - 14, 2015, in Chicago at the Palmer House Hotel.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
